ABOUT US

20|20 OptimEyes Technologies are committed to improving treatments for patients suffering from vision loss and other ocular conditions. Led by a talented team and experienced key advisors, we are de-risking our patented mucoadhesive micelle nanoparticles technology, initially for the treatment of Glaucoma and dry eye disease.

Our business strategy is dual pronged. We are working on internal product development utilizing existing therapeutics, such as cyclosporine A for dry eye disease and latanoprost for glaucoma. We are also interested in external collaborations, using strategic partnerships to examine novel therapeutics with our formulation. These are therapeutics that could benefit from lower doses, controlled release, higher solubility or a reduced dosing regimen.

We also have the capacity to conduct animal testing, allowing us to use your drugs to complete feasibility studies and if successful, proceed immediately into low cost animal studies using our state of the art Phoenix Ganzfeld ERG and Heidelberg Spectralis OCT.